Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

NCT05198609 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

214

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: FOLFOX-HAIC
DRUG: Camrelizumab
DRUG: Apatinib

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]